Clinical trial NCT00887432
Conditions: Prostate Adenocarcinoma
Sponsor: Roswell Park Cancer Institute
Start date: 2009-04-08; Completion date: 2020-06-08
Enrollment: 132 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
This randomized clinical trial studies how well cholecalciferol supplement works in treating patients with localized prostate cancer undergoing observation. Cholecalciferol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly.

Detailed description:
PRIMARY OBJECTIVES:

I. To determine the prostate-specific antigen (PSA) response with oral high dose vitamin D3 supplementation (cholecalciferol) in patients with localized, histologically proven adenocarcinoma of the prostate who have not received any treatment for prostate cancer ever and have chosen expectant management.

SECONDARY OBJECTIVES:

I. To examine the pattern of response of PSA dynamics as well as the absolute change in PSA following vitamin D3 supplementation.

II. Assess the toxicity of vitamin D3 supplementation in men with prostate cancer.

TERTIARY OBJECTIVES:

I. Track occurrence of infections, deep venous thrombosis, vascular events and falls in the study population.

II. To evaluate relationship between cytochrome P450 family 24 (CYP24), 27B1, single-nucleotide polymorphism (SNPs) and serum 25(hydroxy \[OH\]) vitamin D response to oral D3 supplementation.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive cholecalciferol orally (PO) once daily (QD) for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm II.

ARM II: Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.

After completion of study treatment, patients are followed up for 30 days.

Arms: arm 1: Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm II. arm 2: Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.
Interventions: intervention 1: Cholecalciferol intervention 2: Laboratory Biomarker Analysis intervention 3: Patient Observation intervention 4: Placebo Administration intervention 5: Quality-of-Life Assessment intervention 6: Questionnaire Administration
Intervention descriptions: intervention 1: Given PO intervention 2: Correlative studies intervention 3: None intervention 4: Given PO intervention 5: Ancillary studies intervention 6: Ancillary studies

Protocol documents:
Prot_SAP_000.pdf: 
I 128308 AMD # 17
 04/19/18
Page 1 of 31
Randomized Placebo-Controlled, Double-Blind Study Of 
Cholecalciferol Replacement in Patients on Expectant Management 
for Localized Prostate Cancer
Study # I 128308
NCT00887432
Principal Investigator:
James Mohler, MD
Roswell Park Cancer Institute
Elm & Carlton Streets
Buffalo, NY 14263
Initial Protocol Version dated 09/05/08
Amendment #1 dated 01/16/09
Amendment #2 dated 02/11/09
Amendment #3 dated 04/01/09
Amendment #4 dated 05/04/09
Amendment #5 dated 07/29/09
Amendment #6 dated 09/02/09
Amendment #7 dated 10/28/09
Amendment #8 dated 07/08/10
Amendment #9 dated 03/21/13
Amendment #10 dated 07/19/13
Amendment #11 dated 09/19/14
Amendment #12 dated 01/07/15
Amendment #13 dated 09/02/15
Amendment #14 dated 12/7/15
Amendment #15 dated 8/30/17
Amendment #16 dated 03/27/18
Amendment #17 dated 04/19/18
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 2 of 31
Table of Contents
Study Summary
4
1.0 Rationale/Background
7
2.0 Primary Objective
11
3.0 Study Population
11
4.0 Inclusion Criteria
12
5.0 Pre-treatment evaluation
12
6.0 Study design
13
7.0 Criteria for Discontinuation
17
8.0 Drug information
18
9.0 Ethical Requirements
18
10.0 Safety Evaluations
19
11.0 Statistical Analysis
23
12.0 Participant Diary
25
13.0 References
26
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 3 of 31
Abbreviations used in order of appearance
PSA
prostate specific antigen
PSAV
prostate specific antigen velocity
PSADT
prostate specific antigen doubling time
D3-25 hydroxy vitamin D
vitamin D3
SNP
single nucleotide polymorphism
ECOG
eastern cooperative group
AST-ALT
alanine aminotransferase (ALT/SGPT)
BUN
blood urea nitrogen
LDH
lactate dehydrogenase
Ht
height
Wt
weight
BP
blood pressure
TPR
temperature, pulse, respiration
DRE
digital rectal examination
PTH
parathormone
DBBR
data bank and biorepository
NCCN
National Comprehensive Cancer Network
AE
adverse event
SAE
serious adverse event
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 4 of 31
Study Summary
Title: Randomized Placebo-Controlled, Double-Blind Study Of Cholecalciferol Replacement in 
Patients on Expectant Management for Localized Prostate Cancer
Objectives:
Primary Objective
1) To determine PSA response with oral high dose vitamin D3 supplementation in patients with 
localized, histologically proven adenocarcinoma of the prostate that have not received any 
treatment for prostate cancer ever and have chosen expectant management.
 Secondary Objectives
1) To examine the pattern of response of PSA dynamics as well as the absolute change in PSA 
following vitamin D3 supplementation.
2) Assess the toxicity of vitamin D3 supplementation in men with prostate cancer.
Exploratory Objectives
1) Track occurrence of infections, deep venous thrombosis, vascular events and falls in the study 
population.
2) To evaluate relationship between CYP24, 27B1, SNPs and serum 25(OH) vitamin D response 
to oral D3 supplementation.
Study Design: Double-blinded, parallel, placebo controlled randomized 2-group complete cross-
over design with 12 week washout period. 103 patients are expected to enroll over 11 year 
period.
Treatment Plan: Eligible men will be randomly assigned to two groups in 1:1 ratio.
Group A will receive 6,000 IU daily of vitamin D3 provided as 3 capsules of 2000 IU each.
Group B will receive a placebo provided as 3 capsules of a rice based placebo.
Treatment Duration: Participants will be followed for 36 weeks and then crossed over after a 
wash out period of 12 weeks and followed for another 36 weeks.
Number of Participants: Each group will be comprised of approximately 50 men. Those who 
are not able to complete the study will be replaced.
103 patients
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 5 of 31
Dose Modification:
1). If a participant's 25(OH) D3 level reaches > 200ng/ml with 6000 IU or 3 capsules a day, or 
any >grade 3 toxicity possibly related to cholecalciferol develops, 25(OH) D3 or placebo will be 
discontinued for 4 weeks. Treatment will then be resumed at lower dose of 4000 IU or 2 capsules 
a day. If a participant misses some period of time off the study drug, the treatment would be 
resumed such that the participant completes a total of 36 weeks on the study drug.
2). If a participant's 25(OH) D3 level reaches > 200ng/ml with the lower dose modification of 
4000 IU or 2 capsules a day, or any grade 3 toxicity develops, 25(OH) D3 or placebo will be 
discontinued for  4 weeks. Treatment will then be resumed at lower dose of 2000 IU or 1 capsule 
a day.
3). If a participant's 25(OH) D3 level reaches > 200ng/ml with the lower dose modification 
of 2000 IU or 1 capsule a day, or any grade 3 toxicity develops, the participant will then be taken 
off study.
4). Participants that drop out after the first treatment period (36 weeks) will be included in the 
analysis but will require enrolling additional participants such that we have evaluable data on 
100 participant-periods. An intention to treat analysis will be done.
5). If participant misses a daily dose of vitamin D3, or placebo, he should skip it and continue to 
take it as scheduled the following day. The participant should write down the day of the missed 
dose in the diary and should bring the diary with him on the day of physical. If participant misses 
more than 1/3 rd of the doses in 12 week interval, the participant will be taken out of the study 
and will be replaced by another participant.
6). At the end of study, participants may choose to continue taking vitamin D3 replacement per 
personal preferences.
Major Entry Criteria:
1) Any patient with clinically localized, histologically proven adenocarcinoma of prostate who 
has not received any treatment for prostate cancer ever and has chosen active surveillance. 
Treatment for prostate cancer is defined as prostatectomy, androgen deprivation, brachytherapy 
or a full course of external beam irradiation.
2) Age ≥ 18 years
3) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
4) Willingness to comply with study guidelines
5) Willingness and ability to consent
6) 25(OH) D3 level less than 40ng/ml within 3 months of initiation of study. Most recent 25 
hydroxy D level within last 3months will be used.
Exclusion Criteria:
1) History of malabsorption syndrome e.g. pancreatic insufficiency, celiac disease, tropical sprue
2) Creatinine > 2.0mg/dl
3) Corrected serum calcium level >10.5 mg/dL
(Serum Corrected Calcium= Serum Calcium+0.8(4-Serum Albumin)
4) Most recent PSA value more than 18 months ago
5) Prior or current therapy for prostate cancer
6) Documented history of nephrolithiasis within the past 5 years
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 6 of 31
7) Patients receiving finasteride (Proscar) or dutasteride (Avodart) or men who have received 
either agent within 90 days of entry are ineligible.
8) Patients cannot take any additional vitamin D supplementation during study treatment. 
Patients taking >2000IU per day prior to treatment will be ineligible.
Plan of the Study:
Pretreatment Evaluation
1) Signed written informed consent
2) Complete medical history, including diagnosis of prostate cancer, concurrent illness, 
concomitant medications, and allergy history
3) Physical examination, including weight, height, ECOG performance status, temperature, vital 
signs (blood pressure, pulse and respiration rate), and digital rectal examination by patient’s 
urologist
4) 
Serum 
alkaline 
phosphatase, 
aspartate 
aminotransferase 
(AST/SGOT), 
alanine 
aminotransferase (ALT/SGPT), total serum bilirubin, BUN, serum creatinine, electrolytes, 
calcium, phosphorous, total protein, albumin, glucose and LDH; Tumor biomarkers: PSA
5) Imaging studies for potential evaluable disease sites as clinically indicated and at clinician’s 
discretion.
6) Baseline toxicity evaluation to document residual toxicity and baseline symptoms
7) 25(OH) D3 level
8) 24 hour urinary calcium and creatinine
9) Research labs (PTH, serum/DNA/Plasma samples)
10) All pretreatment PSA values done up to 2 years prior to enrollment will be recorded
Toxicity assessment will be done after 4 weeks of enrollment via a telephone assessment, 
thereafter will be done every 12 weeks at a clinic visit. Relevant laboratory data will be repeated 
every 12 weeks (please see the table 6.1). Investigational biomarkers will also be done with these 
laboratory tests every 12 weeks.
Patients will be continued on a treatment group for 36 weeks and then will have a 12 week 
washout period where they will be off any study drug or placebo. After this 12 week washout 
period, patients will be crossed-over with follow up every 12 weeks for another 36 weeks (total = 
84 weeks) with assessments similar to those done at 36 week visit.
Study Duration: 11 years
Study Medication
Oral Vitamin D3 supplementation will be provided as capsules of 2000 IU each (manufacturer- 
Vital Nutrients). Patients will be advised to take 3 capsules once a day to provide 6,000 IU of 
Vitamin D3.
Cholecalciferol is to be taken orally as a single AM dose.
An identical placebo containing rice powder will be provided by the manufacturer.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 7 of 31
1.0 Rationale /Background
1.1 Prostate Cancer and Role of Expectant Management
Prostate cancer is the most common visceral malignancy in American males and is the second 
most common cause of cancer related deaths. It is estimated that 218,890 men will be diagnosed 
with and 27,050 men will die of prostate cancer in 20071 . Many patients are diagnosed with 
prostate cancer based on a screening prostate specific antigen (PSA) test.2 In some patients, an 
abnormal PSA is the only indication of prostate cancer (stage T1c). Localized prostate cancer is 
usually treated with either surgery or radiation.3 4 The necessity of definitive therapies in all men 
with prostate cancer is unclear and certain individuals choose a “watchful waiting” approach for 
their localized disease due to the morbidity sometimes associated with irradiation or 
prostatectomy. There is limited evidence for improved quality or quantity of survival in certain 
population (e.g. elderly men, men with substantial comorbidities).5 Expectant management 
(observation, active surveillance, watchful waiting) is a reasonable option in many situations.6 7 8 
9 10 11 
1.1.1 NCCN Guidelines for Expectant Management
Expectant management involves actively monitoring the course of disease with the expectation 
to intervene if the cancer progresses. Patients with clinically localized cancers who are 
candidates for definitive treatment and choose expectant management should have regular follow 
up as suggested by 2007 updated NCCN guidelines with DRE and PSA every 6 months for life 
expectancy greater than or equal to 10 years and every 6-12 mo for life expectancy < 10 years. 
Needle biopsy of the prostate may be repeated within 6 months of diagnosis if initial biopsy was 
< 10 cores or assessment discordant (e.g. palpable tumor contralateral to side of positive biopsy). 
Needle biopsy may be performed within 18 months if > 10 cores obtained initially, then 
periodically.
Cancer progression may have occurred if any of the following is noted: Gleason grade 4 or 5 
cancer is found upon repeat prostate biopsy; prostate cancer is found in a greater number of 
prostate biopsies or occupies a greater extent of prostate biopsies; PSA doubling time < 3 y or 
PSA velocity is > 0.75; a repeat prostate biopsy is indicated for signs of disease progression by 
exam or PSA.
Advantages of expectant management:

Avoid possible side effects of definitive therapy that may be unnecessary

Quality of life/normal activities retained

Risk of unnecessary treatment of small, indolent cancers is reduced
Disadvantages of expectant management:

Chance of missed opportunity for cure

Risk of progression and/or metastases

Subsequent treatment may be more intense with increased side effects

Increased anxiety

Requires frequent medical exams and periodic biopsies

Uncertain long term natural history of prostate cancer
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 8 of 31
1.2 PSA Velocity and Slope
PSA is a useful marker to identify progressive disease in patients with prostate cancer.12 Studies 
have shown that serum PSA levels correlate with tumor volume and pathologic stage. 13 14 15 In 
addition, a rapid PSA change (expressed as PSA velocity [PSAV] or PSA doubling time 
[PSADT]) was shown to correlate with the presence of cancer and metastatic disease. PSAV is 
defined as rate of change in PSA over a predefined period of time.16 PSA dynamics provides an 
insight into the biological behavior of the tumor and tumor kinetics. There is recent evidence to 
suggest that PSA dynamics is not only useful in prostate cancer detection but also in predicting 
treatment outcomes. Schmid et al. studied serial measurements of PSA in men during at least 1 
year of expectant management, and they found that PSADT was related to tumor stage and 
grade.17 McLaren et al. found that PSADT was the most powerful indicator of clinical 
progression in 113 men observed expectantly; whereas, T classification, histologic grade, and 
initial levels of PSA were not important.18 D’Amico et al reported that a PSAV greater than 2 
ng/ml per year was associated with greater prostate cancer-specific mortality following radical 
prostatectomy and external beam radiation therapy.19 20
PSA slope is defined as the slope of the linear line of log2 (PSA) versus time. The advantage to 
this transformation is the inverse of the slope is the time to doubling the PSA value. 21 22 
Following PSA dynamics can help guide treatment strategy in patients who choose expectant 
management.
1.3 Prostate Cancer and Vitamin D
Multiple studies demonstrate links between vitamin D deficiency and prostate cancer.23 24 25 26 27 
28 29 . 
1.3.1 Vitamin D analogues and in vivo and in vitro growth of prostate cancer:
In preclinical studies, 1, 25 dihydroxyvitaminD3 [calcitriol; 1α,25(OH)2D3] has been shown to 
be effective in killing prostate cancer cells 30 31 32 33 34 35 36. 1α,25(OH)2D3-induces cell-cycle 
arrest of LNCaP cell in the G0–G1 phase involves decreased phosphorylation of the 
retinoblastoma gene-encoded protein (Rb). This is followed by a reduction in the activity of the 
transcription factor, which leads to increased activity of p21waf1, and decreased CDK2 activity. 
Blutt et al. observed apoptosis after treating LNCaP cells with 1α,25(OH)2D3 accompanied by 
down regulation of two anti-apoptotic proteins, Bcl2 and BclXL, and is prevented by 
overexpression of the gene that encodes Bcl2. Other anti-apoptotic proteins (Mcl-1, BAG1L, 
XIAP, cIAP1 and cIAP2) are also down regulated by 1α, 25(OH)2D3 in LNCaP cells but 
proapoptotic Bax and Bak are unaltered . This down regulation leads to the activation of caspase-
3 and caspase-9, the apical proteases in the mitochondrial pathway for apoptosis. Thus, both 
growth arrest and apoptosis are involved in growth regulation of LNCaP cells in response to 1α, 
25(OH)2D3. Studies have also implicated the increased expression of insulin-like growth factor 
binding protein-3 (IGFBP-3) in the growth inhibition induced by calcitriol which in turn 
increases p21Waf/Cip1 expression. Other mechanisms of calcitriol actions in PCa cells include the 
stimulation of differentiation, modulation of growth factor actions and the inhibition of invasion, 
metastasis and angiogenesis.
Similar anti-proliferative effects are seen in vivo in many human, mouse and rat models.37
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 9 of 31
1.3.2. Epidemiological relationship between Vitamin D levels and prostate cancer:
There appears to be an inverse correlation between the mortality rate of prostate cancer and 
exposure to ultraviolet radiation (UVR) in the US population. An association between vitamin D 
deficiency and prostate cancer was reported by Ahonen et al. in a 13-year follow-up of 19 000 
middle-aged men in the Helsinki Heart Study. 27 In this study, 149 cases of prostate cancer were 
identified and matched to 566 sample controls. The study showed that low circulating levels of 
25(OH) D3 (<40 nmol l−1 or 16 ng ml−1) were associated with an increased risk of subsequent 
earlier onset and more aggressive progression of prostate cancer, especially before the age of 52.
UVR exposure has a significant protective effect in prostate cancer.38 Luscombe et al showed 
that cancer patients with the lowest quartile of sun exposure developed cancer at a median age of 
67.7 years compared with 72.1 years in patients in other quartiles.39 Although the mechanism of 
this association is unclear, it is possible that increased cutaneous synthesis of vitamin D3 
increases the circulating levels of 25(OH) D3 and the subsequent formation of 1α, 25(OH)2D3 in 
the prostate by prostatic 1α-OHase (20). 1α, 25(OH)2D3 then interacts with VDR in the prostate 
and induces cell-cycle arrest and apoptosis-suppressing cancer development .40 41 42 Populations 
in whom vitamin D levels are estimated to be low have a greater risk of prostate cancer and other 
cancers.43 The greater risk of prostate cancer in Afro-Caribbean men indicates that one factor 
contributing to the genesis of prostate cancer might be vitamin D insufficiency.44
1.3.3 Clinical Data:
Limited but intriguing clinical data suggest 1α,25(OH)2D3 alone or in combination with other 
agents may slow PSA rise in men with either androgen stimulated or castration resistant prostate 
cancer patients. 45 46 47 48 49 50 51 52 53 NCCN guideline--

We have reported an approximately 25% response rate (PSA) in men with castration 
resistant prostate cancer using a regimen of 12mcg calcitriol 3X/week [MTW] + 
dexamethasone [4mg SMTW].54 

Gross et al using calcitriol and Vieth et al using cholecalciferol showed slowing of PSA 
increase in patients with androgen stimulated prostate cancer. 46 55 

Vieth et al noted that the rate of rise in PSA is slower during the spring-summer than 
during the rest of the year, in men who had been followed on an expectant management 
protocol with selective delayed intervention for clinically localized, low-to-intermediate 
grade prostate cancer.56 
These trials demonstrated that the rate of increase in PSA velocity may be altered by high doses 
of calcitriol. Well tolerated, safe agents are needed that might slow PSA increase. Based on 
above data, it is rational to study the effect of oral calcitriol supplementation on PSA dynamics 
in patients with prostate cancer who have chosen expectant management for clinically localized 
prostate cancer.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 10 of 31
1.4 Vitamin D Supplementation and Toxicity
Supplementation with vitamin D has been studied in normal individuals and those with 
vitamin D deficiency. Recommended daily allowance of vitamin D is 400 IU. Considerable 
data suggests this may be inadequate to bring and maintain serum vitamin D levels in normal 
range.[Hollis et al] The currently accepted normal range of 25(OH) D3 is 32-100ng/mL 
[ng/ml X 2.5  nmol/L]. Supplementation with 10 µg (400 IU) of vitamin D raises 25(OH) D 
by only 0.45 nmol/(L μg day).

Various studies report that one minimal erythema dose( Exposure of the body in a 
bathing suit to sunlight that causes a minimum redness to the skin) of UV-B radiation to 
the whole body produces between 10,000 and 25,000 IU (250 and 625 μg) of 
cholecalciferol and is safe. 57 Indeed, a continuing daily oral intake of 10,000 IU 
produces a mean serum 25OHD value approximating what is seen naturally after 
extensive summer sun exposure at mid latitudes.58

All instances of vitamin D toxicity have involved serum 25(OH) D concentrations more 
than 250nmol/L, a value that would be produced only at continuing oral intakes in excess 
of 10,000IU (250microg)/day.59

To attain a steady state of equilibrium in serum Vitamin D level, at least 3 months are 
required post a change in vitamin D supplementation dose.60 The graph below depicts the 
same with varying doses of oral vitamin D supplementation. 61

The serum 25 (OH) D concentrations is maintained within a narrow range 
75–220 
nmol/L across a wide range of D3 intake: 20 µg (800 IU) to 500 µg (20000 IU)/d. The 
following graph clearly demonstrates that it is very safe to treat patients with vitamin D 
up to dosage of 10,000 IU-especially if 25(OH)D3 levels are monitored. 56 The serum 
levels appear to plateau between 120-130 nmol/L. Several studies have demonstrated the 
essential safety of continuous daily dosing with 4000, 5000 and 10,000 IU/day (100, 125 
and 250 μg/day) for up to 16 weeks, and of 50,000 IU (1250 μg)/day for 8 weeks, all 
without evidence of toxicity. 62 63 64
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 11 of 31
Figure 4. Effect of the duration of vitamin D supplementation on the mean serum 25-
hydroxyvitamin D [25(OH)D] concentration achieved. Vitamin D intakes for the groups were as 
follows: 10 µg (400 IU)/d (+; 28), 25 µg (1000 IU)/d (X; 28), 50 µg (2000 IU)/d ( ; 64), 250 µg 
(10000 IU)/d (28).
2.0  Primary Objective
1) To determine the PSA response with oral high dose vitamin D3 supplementation in patients 
with localized, histologically proven adenocarcinoma of the prostate who have not received any 
treatment for prostate cancer ever and have chosen expectant management.
2.1 Secondary Objectives
1) To examine the pattern of response of PSA dynamics as well as the absolute change in PSA 
following vitamin D3 supplementation. 
2) Assess the toxicity of vitamin D3 supplementation in men with prostate cancer.
2.2 Exploratory Objectives
1) Track occurrence of infections, deep venous thrombosis, vascular events and falls in the study 
population.
2) To evaluate relationship between CYP24, 27B1, SNPs and serum 25(OH) vitamin D response 
to oral D3 supplementation.
3.0 Study Population
Patients with prostate cancer who have chosen to undergo expectant management for their 
disease will be eligible. Patients who are not able to complete the study will be replaced.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 12 of 31
4.0 Inclusion Criteria
1) Any patient with clinically localized, histologically proven adenocarcinoma of prostate who 
has not received any treatment for prostate cancer ever and has chosen active surveillance. 
Treatment for prostate cancer is defined as prostatectomy, androgen deprivation, brachytherapy 
or a full course of external beam irradiation
2) Age ≥ 18 years
3) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
4) Willingness to comply with study guidelines
5) Willingness and ability to consent
6) 25(OH) D3 level less than 40ng/ml within 3 months of initiation of study. Most recent 25 
hydroxy D level within last 3 months would be used.
4.1 Exclusion Criteria
1) History of malabsorption syndrome e.g. pancreatic insufficiency, celiac disease, tropical sprue
2) Creatinine > 2.0mg/dl
3) Corrected serum calcium level of >10.5 mg/dL
 (Serum Corrected Calcium = Serum Calcium + 0.8(4-Serum Albumin)
4) Most recent PSA value more than 18 months ago
5) Prior or current therapy for prostate cancer
6) Documented history of nephrolithiasis within the past 5 years
7) Patients receiving finasteride (Proscar) or dutasteride (Avodart) or men who have received 
either agent within 90 days of entry are ineligible. 
8) Patients cannot take any additional vitamin D supplementation during study treatment. 
Patients taking >2000IU per day prior to treatment will be ineligible.
5.0 Pre-treatment evaluation
All evaluations should be done within 4 weeks of registration unless otherwise noted. 
1) Signed written informed consent. All patients will have the option to participate in the 
DBBR/Vitamin D trial.
2) Complete medical history, including diagnosis of prostate cancer, concurrent illness and 
concomitant medications.
3) Physical examination, including weight, height, ECOG performance status, temperature, vital 
signs (blood pressure, pulse and respiration rate), and digital rectal examination by patient’s 
urologist
4) 
Serum 
alkaline 
phosphatase, 
aspartate 
aminotransferase 
(AST/SGOT), 
alanine 
aminotransferase (ALT/SGPT), total serum bilirubin, BUN, serum creatinine, electrolytes, 
calcium, phosphorous, total protein, albumin, glucose and LDH; Tumor biomarkers: PSA
5) Imaging studies for potential evaluable disease sites as clinically indicated
6) Baseline toxicity evaluation to document baseline symptoms
7) 25(OH) D3 level
8) 24 hour urinary calcium and creatinine
9) Research labs (PTH, serum/DNA/Plasma samples)
10) All pretreatment PSA values done up to 2 years prior to enrollment will be recorded.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 13 of 31
5.1 Registration
Following evaluation and informed consent the patient will be registered. At the time of 
registration, the following information will be recorded:
1. Patient’s name and medical record number
2. Patient’s date of birth
3. Date of commencement of the protocol
4. Stage and Gleason score of prostate cancer
5. To which treatment arm patient is assigned
Eligibility criteria will be verified at the time of registration. A case number will be assigned 
following registration.
6.0 Study design
Study design
Double-blinded, parallel, placebo controlled randomized 2-group complete cross-over design 
with 12 week washout period.
Participant Assignment
Eligible patients will be randomly assigned to two groups in 1:1 ratio.
Group A will receive 6,000 IU daily of vitamin D3 (3 capsules of 2000 IU pills).
Group B will receive an identical placebo.
Each group will be comprised of approximately 50 patients. Patients who are not able to 
complete the study will be replaced.
Cross-over will be done after a period of 36 weeks followed by 12 weeks washout period.  After 
12 week washout period, patients on either arm will be crossed over to receive the drug on the 
other arm (patients who were on vitamin D arm will get crossed-over to receive placebo, while 
patients on placebo arm will be crossed-over to receive vitamin D).
They will be stratified randomization based on the Gleason score (less than or equal to 6, OR 
greater than 6) as well as the season of entry (winter/spring versus summer/fall). Seasonal 
stratification assignment will be based on the date of randomization:
If randomized between 12/22 and 6/21, it will be considered the winter/spring group and 
if randomized between 6/22 and 12/21 it will be the summer/fall group.
After completion of study, patient may choose to continue vitamin D if they desire.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 14 of 31
103 patients
Duration of the trial
Patients will be followed for 36 weeks after randomization followed by a washout period of 12 
weeks and then be crossed over and followed for an additional 36 weeks (total 84 weeks). 103 
patients are expected to enroll over an 11 year period.
Dose Modification:
1). If a patient's 25(OH) D3 level reaches > 200ng/ml with 6000 IU or 3 capsules a day, or 
any >grade 3 toxicity possibly related to cholecalciferol develops, 25(OH) D3 or placebo will be 
discontinued for 4 weeks. Treatment will then be resumed at lower dose of 4000 IU or 2 capsules 
a day. If a patient misses some period of time off the study drug, the treatment will be resumed 
such that the patient completes a total of 36 weeks on the study drug.
2). If a patient's 25(OH) D3 level reaches > 200ng/ml with the lower dose modification of 
4000 IU or 2 capsules a day, or any grade 3 toxicity develops, 25(OH) D3 or placebo will be 
discontinued for  4 weeks. Treatment will then be resumed at lower dose of 2000 IU or 1 capsule 
a day.
3). If a patient's 25(OH) D3 level reaches > 200ng/ml with the lower dose modification 
of 2000 IU or 1 capsule a day, or any grade 3 toxicity develops, the patient will then be taken off 
study.
4). Patients that drop out after the first treatment period (36 weeks) will be included in the 
analysis but will require enrolling additional patients such that we have evaluable data on 100 
patient-periods. An intention to treat analysis will be done.
5). If patient misses a daily dose of vitamin D3, or placebo, he should skip it and continue to take 
it as scheduled the following day. The patient should write down the day of the missed dose in 
the diary and should bring the diary with him on the day of physical. If patient misses more than 
1/3 rd of the doses in a 12 week period, the patient will be taken out of the study and will be 
replaced by another patient.
6). At the end of study, patients may choose to continue taking vitamin D3 replacement per 
personal preferences.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 15 of 31
6.1 Study Schedule: Pre-treatment evaluations are described in section 5.0 and are repeated here for sake of convenience.
Parameters 
Pre-studye
 
4 weeks
(+/- 7 days)
12 weeks
(+/- 7 days)
24 weeks
(+/- 7 days)
36 weeks
(+/- 7 days)
4 weeks f/ua
(+/- 7 days)
Physical Exam, Medical History,
Vital Signs and ECOG(Wt,  temperature, BP, 
pulse and respiration rate)  
X
X
Height
X
Toxicity assessment
X
Xª
X
X
X
Xa
Serum alkaline phosphatase, aspartate 
aminotransferase (AST/SGOT), alanine 
aminotransferase (ALT/SGPT), total serum 
bilirubin, BUN, serum creatinine, electrolytes, 
calcium, phosphorous, total protein, albumin, 
glucose and LDH
X
X
X
X
Serum 25(OH)D3 
X
X
X
X
PTHb
X
X
X
X
PSA
X
X
X
X
24 hr urinary calcium and creatinine
X
X g
X g
X
Assessment of infection, fall, fracture, 
thrombosis
X
X
X
X
Investigational Biomarker 
samples b, c and DBBR Blood Draw 
X
X
X
X
X
Radiographic study( Computed tomography 
and/ or bone scan)f
X
X
X
X
Study drug compliance assessment
X
X
X
X
Nurse visit: ECOG, Wt, temperature & BP
X
X
a-
Telephone assessment
b-
Performed in the lab. See Sec. 6.1 “Monitoring”
c-
DNA, serum, plasma isolated through ongoing Vitamin D assessment protocol (only for patients at Roswell Park).
d-
After a wash-out period of 12 weeks, patients will be crossed over. Patients would be followed every 12 weeks with similar plan.
e-
Pre study evaluations are to be done within 4 weeks of registration. Complete history to be done at pre study evaluation.
f-
If clinically indicated. CT/Bone scan to be done at the clinician’s discretion.
g-
Needed only if serum Ca level increases and it is per clinician’s discretion.


I 128308 AMD # 17
 04/19/18
Page 16 of 31
All evaluations should be done within 4 weeks of registration unless otherwise noted.
1. Signed written informed consent. Roswell Park patients will have the option to 
participate in DBBR/Vitamin D trial.
2. Complete medical history, including diagnosis of prostate cancer, concurrent illness 
and concomitant medications.
3. Physical examination, including weight, height, ECOG performance status, 
temperature, vital signs (blood pressure, pulse and respiration rate), and digital rectal 
examination by patient’s urologist
4. Serum alkaline phosphatase, aspartate aminotransferase (AST/SGOT), alanine 
aminotransferase  
(ALT/SGPT), total serum bilirubin, BUN, serum creatinine, 
electrolytes, calcium, phosphorous, total protein, albumin, glucose and LDH; Tumor 
biomarkers: PSA
5. Imaging studies for potential evaluable disease sites as clinically indicated
6. Baseline toxicity evaluation to document baseline symptoms
7. 25(OH) D3 level
8. 24 hour urinary calcium and creatinine
9. Research labs (PTH, serum/DNA/Plasma samples).
10. All pretreatment PSA values done up to 2 years prior to enrollment will be recorded.
Toxicity assessment will be done after 4 weeks of enrollment via a telephone assessment, 
thereafter would be done on every 12 week basis at clinic visit. Doses remaining will be 
assessed at each clinic visit and compliance ensured by telephone check by clinical 
research Coordinator. Laboratory data (as pre-study evaluation) will be repeated every 12 
weeks. Investigational biomarkers will also be done with these laboratory tests on every 
12 weeks basis.
Patients will continue on treatment for 36 weeks and then will have a 12 week washout 
period where they will be off any study drug or placebo. After 12 week washout period, 
patients will be crossed-over with follow up every 12 weeks for another 36 weeks (total 
=84 weeks) with assessments similar to those done at 36 weeks follow-up visit.
Prior studies have used similar design and there are substantial data that indicate that  36 
weeks is a time period over which modification of PSA slope can be assessed. 65, 66 In 
extensive vitamin D literature there are substantial data to indicate that "equilibrium" is 
achieved in 25(OH)D3 levels after a 12 weeks equilibration period. The literature 
indicates that 3 months is adequate "washout" to re-establish serum levels. 60, 61 The half-
life of 25(OH)D3 in the circulation is reported as 1 mo in humans, the results for the 
submariners suggest a 2-mo half-life.67, 68. Conventional pharmacology indicates it should 
take 4 half-lives before a drug's equilibrium is achieved. Unlike a conventional drug, 
25(OH)D3 is a metabolite whose concentration can be altered through balance between 
its production and clearance so that an equilibrium can be achieved earlier than would be 
expected from the half-life. 69,70 
Monitoring
Parameters noted in the above table will be assessed as per standard clinical laboratory 
procedures. 25(OH) D3 levels will be measured in the hospital chemistry laboratory and 
are the standard measure for determination of vitamin D health. PTH levels after basal 
level will be measured as a research test in the lab of Dr. Johnson.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 17 of 31
Procedure for collecting serum samples for PTH measurements.
Collect 5 mL blood in a red top tube (no additives). It is recommended that all samples to 
be collected A.M (to avoid diurnal variation issues). Blood samples are spun in a 
refrigerated centrifuge at 2000 x g for 10 min. Divide serum into two aliquots of 1.0 mL 
each/ patient (this avoids repetitive freezing and thawing every time the assay is 
performed). Freeze immediately at -70°C in plastic tubes. Under these storage conditions 
PTH is stable for up to 11 months.
Please call 845-1257 to notify Dr. Johnson’s lab of impending sample or if there are 
questions.
In addition all patients will be offered to enroll, after informed consent, on the DBBR-
vitamin D repository trial.
PSA Measurement
Once enrolled on study, individual patients should get their PSA drawn at the same 
laboratory to ensure correct calculation of PSA dynamics for that individual.
Correlative/Special Studies
Blood samples will be collected and stored for future studies by the RPCI Data Bank and 
BioRepository (DBBR) for Roswell Park patients only, per Standard Operating 
Procedures for vitamin D trial banking. The DBBR is a shared resource (RPCI protocol I 
03103), where participants are consented to donate blood for research (prior to and 
following treatments), to complete an epidemiologic questionnaire, and to give 
permission to have their blood specimens linked to the questionnaire and clinical data 
including diagnosis and laboratory test results for research. Collected biospecimens 
and/or data are provided to investigators with RPCI IRB approved research protocols.
7.0 Criteria for Discontinuation
1) Patient does not comply with study guidelines.
2) Patient wants to withdraw
3) Unacceptable side effects attributed to study treatments. e.g. development of 
genitourinary stones or grade 2 or higher hypercalcemia
4) Patient unable to tolerate the drug. e.g. persistent nausea and vomiting for more than 
48hrs or any grade 3 or higher toxicity attributed to study drug.
5) Creatinine ≥ 2.5 X baseline.
6) Need for any active treatment for prostate cancer on clinician’s discretion.
7.1 Criteria for initiation of more aggressive treatment
1) PSADT < 3year.
2) Tumor grade progression (e.g. Gleason = or > 7).
3) Clinical progression.
4) Patient choice.
5) Physician discretion.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 18 of 31
8.0  Drug information
8.1 Vitamin D3 (Cholecalciferol)
Availability
Vitamin D3 is the standard replacement approach and would be utilized for the 
purpose of our study. Oral Vitamin D3 supplementation will be provided as capsules 
provided by Vital Nutrients. Patients will be advised to take 3 capsules once a day to 
provide 6,000 IU of Vitamin D3.
Administration
Cholecalciferol is to be taken orally as a single AM dose.
Side Effects of Cholecalciferol
Reported side effects are all related to hypercalcemia which can result in nausea, 
vomiting, constipation, polyuria, nocturia, polydipsia, hypercalcemia and genitourinary 
stones and rarely cardiac arrhythmias. Refer to product monograph for more details.
8.2 Placebo
Oral placebo will be available in rice powder based capsules which appear identical to 
vitamin D capsules. It will again be dispensed as 3 capsules a day as a single AM dose.
8.3 Drug Availability
Cholecalciferol (D3) and identical placebo are available as capsules provided by Vital 
Nutrients.
8.4 Drug ordering:
Cholecalciferol (D3) is commercially available but will be provided free of charge to 
patient enrolled in this clinical trial. It will be ordered by the Investigational Drug Service 
through the appropriate grant.
8.5 Agent Inventory records:
The IDS will maintain inventory and dispensing records on the NIH2564 DARF. 
8.6 Administration:
Cholecalciferol (D3) and placebo will be taken orally.
9.0 Ethical Requirements
The participant must give a written, informed consent to participate in study. Participants 
may withdraw from the study at any time, for any reason, without prejudice to their 
present or future care. In outlining the study, the principal investigator will explain the 
treatment plan; the potential hazards and benefits to the patient and proposed visit 
schedule to evaluate the effects of the study. Informed consent will be signed by the 
participant and an investigator.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 19 of 31
10.0 SAFETY EVALUATION
10.1 Adverse Events
An adverse event or adverse experience (AE) is any untoward medical occurrence 
associated with the use of a drug in humans, whether or not considered drug related. 
Therefore, an AE can be ANY unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not considered related to the medicinal 
(investigational) product (attribution of ‘unrelated’, ‘unlikely’, ‘possible’, ‘probable’, or 
‘definite’).
An AE is considered “unexpected” if it is not listed in the investigator brochure or is not 
listed at the specificity or severity that has been observed; or if an investigator brochure is 
not required or available, is not consistent with the risk information described in the 
general investigational plan in other study-related documents.
10.1.1 Diagnosis Versus Signs and Symptoms
If known, a diagnosis should be recorded on the CRF rather than individual signs and 
symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and 
elevated transaminases). However, if a constellation of signs and/or symptoms cannot be 
clinically characterized as a single diagnosis or syndrome at the time of reporting, each 
individual event should be recorded as an AE or SAE on the CRF. If a diagnosis is 
subsequently established, it should be reported as follow-up information.
10.1.2 Adverse Events Occurring Secondary to Other Events
In general, AEs occurring secondary to other events (e.g., cascade events or clinical 
sequelae) should be identified by their primary cause. For example, if severe diarrhea is 
known to have resulted in dehydration, it is sufficient to record only diarrhea as an AE or 
SAE 
on 
the 
CRF. 
However, clinically significant AEs occurring secondary to an initiating event that are 
separated in time should be recorded as independent events on the CRF. For example, if a 
severe gastrointestinal hemorrhage leads to renal failure, both events should be recorded 
separately on the CRF.
10.1.3 Abnormal Laboratory Values
Only clinically significant laboratory abnormalities that require active management will 
be recorded as AEs or SAEs on the CRF (e.g., abnormalities that require study drug dose 
modification, discontinuation of study treatment, more frequent follow-up assessments, 
further diagnostic investigation, etc.).
If the clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5 x the upper limit of normal associated with 
cholecystitis), only the diagnosis (e.g., cholecystitis) needs to be recorded on the Adverse 
Event CRF.
If the clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded as an AE or SAE on the CRF. If the laboratory 
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 20 of 31
abnormality can be characterized by a precise clinical term, the clinical term should be 
recorded as the AE or SAE. For example, an elevated serum potassium level of 7 mEq/L 
should be recorded as “hyperkalemia”.
Observations of the same clinically significant laboratory abnormality from visit to visit 
should not be repeatedly recorded as AEs or SAEs on the CRF, unless their severity, 
seriousness, or etiology changes.
10.1.4 Preexisting Medical Conditions (Baseline Conditions)
A preexisting medical condition should be recorded as an AE or SAE only if the 
frequency, severity, or character of the condition worsens during the study. When 
recording such events on an Adverse Event CRF, it is important to convey the concept 
that the preexisting condition has changed by including applicable descriptors 
(e.g., “more frequent headaches”).
10.2 Grading and Reporting Adverse Events
10.2.1 Grading and Relationship to Drug
The descriptions and grading scales found in the CTEP Version 5.0 of the NCI Common 
Terminology Criteria for Adverse Events (CTCAE) will be utilized for AE reporting. 
CTEP Version 5.0 of the CTCAE is identified and located at:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
AEs not covered by specific terminology listed should be reported with common medical 
terminology, and documented according to the grading scales provided in the CTCAE 
Version 5.0.
The relationship of event to study drug will be documented by the Investigator as 
follows:

Unrelated: The event is clearly related to other factors such as the participant’s 
clinical state, other therapeutic interventions or concomitant drugs administered to 
the participant.

Unlikely: The event is doubtfully related to investigational agent(s). The event 
was most likely related to other factors such as the participant’s clinical state, 
other therapeutic interventions, or concomitant drugs.

Possible: The event follows a reasonable temporal sequence from the time of 
drug administration, but could have been produced by other factors such as the 
participant’s clinical state, other therapeutic interventions or concomitant drugs.

Probable: The event follows a reasonable temporal sequence from the time of 
drug administration, and follows a known response pattern to the study drug. The 
event cannot be reasonably explained by other factors such as the participant’s 
clinical state, therapeutic interventions or concomitant drugs.

Definite: The event follows a reasonable temporal sequence from the time of drug 
administration, follows a known response pattern to the study drug, cannot be 
reasonably explained by other factors such as the participant’s condition, 
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 21 of 31
therapeutic interventions or concomitant drugs; AND occurs immediately 
following study drug administration, improves upon stopping the drug, or 
reappears on re-exposure.
10.3 Reporting Adverse Events:
Routine AEs occurring between the start date of intervention until 30 days after the last 
intervention, or until the event has resolved, the study participant is lost to follow-up, the 
start of a new treatment, or until the study investigator assesses the event(s) as stable or 
irreversible, will be reported. New information will be reported after it is received.

Guidelines for Routine Adverse Event Reporting for Phase 1 Studies 
(Regardless of Expectedness)
Attribution
Grade 1
Grade 2
Grade 3
Grade 4
Unrelated
X
X
X
X
Unlikely
X
X
X
X
Possible
X
X
X
X
Probable
X
X
X
X
Definite
X
X
X
X

Guidelines for Routine Adverse Event Reporting for Pilot, Phase 2, and 
Phase 3 Studies (Regardless of Expectedness)
Attribution
Grade 1
Grade 2
Grade 3
Grade 4
Unrelated
X
X
Unlikely
X
X
Possible
X
X
X
X
Probable
X
X
X
X
Definite
X
X
X
X
10.4 Serious Adverse Events
A serious adverse event (SAE) is any adverse event (experience) that in the opinion of 
either the investigator or sponsor results in ANY of the following:

Death.

A life-threatening adverse event (experience). Any AE that places a participant or 
participants, in the view of the Investigator or sponsor, at immediate risk of death 
from the reaction as it occurred. It does NOT include an AE that, had it occurred 
in a more severe form, might have caused death.

Inpatient hospitalization or prolongation of existing hospitalization (for 
> 24 hours).
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 22 of 31

A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions.

A congenital anomaly or birth defect.

Important Medical Event (IME) that, based upon medical judgment, may 
jeopardize the participant and may require medical or surgical intervention to 
prevent one of the outcomes listed above.
10.4.1 Reporting Serious Adverse Events
All new SAEs occurring from the date the participant signs the study consent until 
30 days after the last intervention or a new treatment is started, whichever comes first, 
will be reported. The Roswell Park SAE Source Form is to be completed with all 
available information, including a brief narrative describing the SAE and any other 
relevant information. 
SAEs occurring after the 30 day follow-up period that the investigator determines to be 
possibly, probably or definitely related to the study intervention should be reported.
SAEs identified as an Unanticipated Problem by the Investigator must be reported. Please 
refer to Section 10.6 for details on reporting Unanticipated Problems.
10.5 Follow-Up for Serious Adverse Events
All related SAEs should be followed to their resolution, until the study participant is lost 
to follow-up, the start of a new treatment, or until the study investigator assesses the 
event(s) as stable or irreversible. New information will be reported when it is received.
10.6 Unanticipated Problems
An Unanticipated Problem (UP) is any incident, experience, or outcome that meets all of 
the following criteria:

Unexpected (in terms of nature, severity, or frequency) given:
a.
The research procedures that are described in the study-related documents, 
including study deviations, as well as issues related to compromise of 
participant privacy or confidentiality of data.
b. The characteristics of the participant population being studied.

Related or possibly related to participation in the research (possibly related means 
there is a reasonable possibility that the incident, experience, or outcome may 
have been caused by the procedures involved in the research).

Suggests that the research places participants or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously 
known or recognized and if in relation to an AE is also deemed Serious per 
Section 17.4.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 23 of 31
10.6.1 Reporting Unanticipated Problems:
The Reportable New Information (RNI) Form will be submitted to the CRS Compliance 
Office within 1 business day of becoming aware of the Unanticipated Problem. After 
review, CRS Compliance will submit the RNI to the IRB.
When becoming aware of new information about an Unanticipated Problem, submit the 
updated information to CRS Compliance with an updated Reportable New Information 
Form. The site Investigator or designated research personnel will report all unanticipated 
problems to the IRB in accordance with their local institutional guidelines.
10.7 Data Safety and Monitoring
If any literature becomes available which suggests that conducting this trial is no longer 
ethical, the study will be terminated and the IRB will be notified of the new findings. The 
IRB will be notified of any change in the risk/benefit ratio that would affect whether the 
study should continue. All serious adverse events will be reported to the IRB according to 
the established guidelines. A cumulative summary of all adverse events occurring on this 
study will also be submitted to the IRB at six months review. Toxicity is reported, as 
required, to the FDA. All study data reviewed and discussed during these meetings will 
be kept confidential. Any breech in participant confidentiality will be reported to the IRB.
11. Statistical Analysis
Power analysis:
A 2x2 cross-over design with total sample size 100 achieves approximately 80% power 
to detect 0.5 effect size (the relative magnitude of the effect under the alternative) at 
significance level 0.05. In other words, assuming the Log2(PSA) slope prior to therapy is 
0.7 ng/ml/yr. with a standard deviation as 0.7 (based on statistical evaluation of data 
provided by Dr. Vieth from his trial of cholecalciferol replacement in men with PSA 
rising after local therapy. 55 , this design is able detect a 50% reduction of PSA doubling 
time. 71 
Statistical analysis plan:
This is 2 by 2 cross over trial. To address the research objectives, we want to pool 
information across periods by taking account of the correlation among repeated responses 
for each individual. The Log2(PSA) will be analyzed by linear mixed model in which the 
fixed effects include treatment (1 for vitamin D3, 2 for control), period (0 for pre study, 1 
for first  36 weeks and 2 for second  36 weeks), time (as a continuous variable), time and 
period interaction, and a variable indicating carry-over effect (1 if the previous treatment 
assignment is vitamin D3, 2 if the previous treatment assignment is control). The random 
effect includes random intercept and slope (and a quadratic term if necessary). The 
significance in the difference between PSA responses for vitamin D3 group and control 
groups will be assessed by approximate t tests. This will be done using SAS PROC 
MIXED (SAS 9.1.3., SAS Institute Inc., Cary, NC, USA). The pattern of response of 
PSA dynamics as well as the absolute change in PSA following vitamin D3 
supplementation will be analyzed similarly using the mixed model approach.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 24 of 31
In addition to the data analysis described above which analyze Log2(PSA), for the men 
who have 3 or more PSA values from the same laboratory over a period of  18 months or 
more prior to enrollment, PSA velocity (PSAV) will be calculated and compared to a 
PSA velocity obtained by analysis of the PSA's during the 2 periods of investigation on 
the study (the  36 weeks on placebo and the  36 weeks on treatment). Specifically, PSAV 
can be analyzed as a summary statistics as follows: PSAV will be calculated for the pre-
study period, the first 36 week study period, and the second 36 week study period for 
each participant by simple linear regression. As a preliminary step, summary statistics 
such as sample mean and standard deviations will be calculated for each group at each 
period (pre study, first 36 weeks, and second 36 week). Furthermore, the difference in the 
PSAV caused by vitamin D3 treatment will be tested using two-sample t test comparing 
the means of differences (first 36 week - second 36 week) in PSAV for the first group 
(vitamin D3 treatment then control sequence) and the second group (control then vitamin 
D3 treatment sequence).
The toxicity will be compared as difference in proportion with 95% confidence intervals.
Survival would be evaluated on an exploratory basis but no comparison would be made 
between groups. Relationship between CYP24, 27B1, SNPs and serum 25(OH)D3 
vitamin D response to oral D3 supplementation will again be done as an exploratory 
analysis. We are developing assays to help in this regards and methods for these 
exploratory analysis would be added as these assays are formulated.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 25 of 31
12. PARTICIPANT DIARY
Study Title: Randomized Placebo-Controlled, Double-Blind Study Of 
Cholecalciferol Replacement in Patients on Expectant Management for 
Localized Prostate Cancer

Take 3 pills daily in the morning

Return pill bottles and diaries at your next clinic appointment
DATE
Time AM 
Dose
Comments /Symptoms/ Missed Dose
____________________________________________________
Participant Signature
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 26 of 31
13. References
1 Cancer facts and figures 2007.American Cancer Society, 2007
2 Andriole GL. Serum prostate-specific antigen: the most useful tumor marker. J Clin 
Oncol . 1992; 10: 1205-1207. 
3 Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men 
with clinically localized prostate cancer. Multi-institutional pooled analysis. JAMA . 
1996; 276: 615-619.
4 Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized 
prostate cancer. A multi-institutional pooled analysis. JAMA . 1999;281: 1598-1604
5 Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or 
radiotherapy for prostate cancer: results from the prostate cancer center outcomes study. J 
Natl Cancer Inst . 2000; 92: 1582-1592.
6 Abbas F, Scardino PT. The natural history of clinical prostate carcinoma. Cancer . 
1997; 80: 827-833
7 Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of 
clinically localized prostate cancer. N Eng J Med . 1994; 330: 242-248.
8 Adolfsson J, Steineck G, Hedlund P-O. Deferred treatment of clinically localized low-
grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska 
series. Urology . 1997; 50: 722-726. 
9 Johansson J-E, Holmberg L, Johansson S, Bergstrom R, Adami H-O. Fifteen-year 
survival in prostate cancer. A prospective, population-based study in Sweden. JAMA . 
1997;277: 467-471
10 Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical 
prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 
2002;347:781-789.
11 Graversen PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO. Radical prostatectomy 
versus expectant primary treatment in stages I and II prostatic cancer: a fifteen-year 
follow-up. Urology 1990;36:493-498
12 Coakley FV, Chen I, Qayyum A, et al. Validity of prostate-specific antigen as a tumour 
marker in men with prostate cancer managed by watchful-waiting: correlation with 
findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. BJU 
Int. 2007 Jan;99(1):41-5.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 27 of 31
13 T.A. Stamey, N. Yang, A.R. Hay et al., Prostate-specific antigen as a serum marker for 
adenocarcinoma of the prostate. N Engl J Med 317 (1987), pp. 909–916. 
14A.W. Partin, H.B. Carter, D.W. Chan et al., Prostate specific antigen in the staging of 
localized prostate cancer: influence of tumor differentiation, tumor volume and benign 
hyperplasia. J Urol 143 (1990), pp. 747–758. 
15 A.W. Partin, J. Yoo, H.B. Carter et al., The use of prostate specific antigen, clinical 
stage and Gleason score to predict pathological stage in men with localized prostate 
cancer. J Urol 150 (1993), pp. 110–114.
16 Benecchi L. PSA velocity and PSA slope. Prostate Cancer Prostatic Dis. 
2006;9(2):169-72. Epub 2006 Mar 28 
17 Schmid H-P, McNeal JE, Stamey TA. Observations on the doubling time of prostate 
cancer. The use of serial prostate-specific antigen in patients with untreated disease as a 
measure of increasing cancer volume. Cancer . 1993;71: 2031-2040.
 
18 McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful 
progression? Prostate specific antigen doubling times and clinical behavior in patients 
with early untreated prostate cancer. Cancer . 1998;82: 342-348. 
19 D’Amico AV, Renshaw AA, Sussman B and Chen MH. Pretreatment PSA velocity and 
risk of death from prostate cancer following external beam radiation therapy, JAMA 
2005: 294 440.
20D’Amico AV, Chen MH, Roehl KA and Catalona WJ, Preoperative PSA velocity and 
the risk of death from prostate cancer after radical prostatectomy, N Engl J Med 2004; 
351: 125.
 
21 Takamiya R, Weinberg V, Young D, Sandler H, McLaughlin P, Roach M. A zero PSA 
slope in posttreatment prostate-specific antigen supports cure of patients with long-term 
follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat 
Oncol Biol Phys 2003; 56: 1073–1078.
22 Taylor JMG,Griffith KA and Sandler HM, Definitions of biochemical failure in 
prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001), pp. 
1212–1219.
23 Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention 
Am J of Public Health. 2006 Feb; 96(2):252-61.
24 Giovannucci, E. The epidemiology of vitamin D and cancer incidence and mortality: a 
review. Cancer Causes & Control 2005 Mar 16(2):83-95.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 28 of 31
25 Moon SJ, Fryer AA and Strange RC. Ultraviolet radiation: effects on risks of prostate 
cancer and other internal cancers. Mutat Res 2005 Apr1; 571(1-2):207-19, 2005 Apr 1
26Schwartz GG and Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? 
(Hypothesis). Anticancer Res. 1990 Sep-Oct; 10(5A):1307-11. 
27 Ahonen MH, Tenkanen L, Teppo L, Hakama M and Tuohimaa P. Prostate cancer risk 
and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 
2000 Oct;11(9):847-52
28 Pole CC and Weigel NL. Vitamin D and prostate cancer. J. Androl. 2002 Jan-
Feb;23(1):9-17 
29 Beer TM, Garzotto M, Park B, et al. Effect of calcitriol on prostate-specific antigen in 
vitro and in humans. Clin Cancer Res. 2006 May 1;12(9):2812-6.
30Zhuang SH and Burnstein KL. Antiproliferative effect of 1α,25-dihydroxyvitamin D3 in 
human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 
activity and persistent G1 accumulation. Endocrinology 1998 Mar;139(3):1197-207. 
31 Guzey M,Kitada S and Reed JC. Apoptosis induction by 1α,25-dihydroxyvitamin D3 in 
prostate cancer. Mol. Cancer Ther. 2002 Jul;1(9):667-77.
32 Blutt SE, McDonnell TJ, Polek TC and Weigel NL. Calcitriol-induced apoptosis in 
LNCaP cells is blocked by overexpression of bcl-2. Endocrinology 2000 Jan;141(1):10-7
33 Yang ES and Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate 
cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J 
Biol Chem. 2003 Nov 21;278(47):46862-8
34 Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 
dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. 
Endocrinology, 1993;132:1952–60
35 Krishnan AV, Peehl DM, Feldman D. The role of vitamin D in prostate cancer.
Recent Results Cancer Res. 2003; 164:205-21.
36 Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin 
D: Regulation of target gene expression. J Cell Biochem. 2003 Feb 1; 88(2):363-71. 
37 Konetty BR, Lavelle JP, Pertskalaishvili G, et al. Effects of vitamin D (calcitriol) on transitional cell 
carcinoma of the bladder in vitro and in vivo. J Urol. 2001 Jan;165(1):253-8.
38 Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate 
doses of solar ultraviolet-B radiation. Cancer 2002 Mar 15;94(6):1867-75
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 29 of 31
39 Luscombe CJ, Fryer AA, French ME et al., Exposure to ultraviolet radiation: 
association with susceptibility and age at presentation with prostate cancer. Lancet 2001 
Aug 25; 358(9282):641-2.
40 Miller GJ. Vitamin D and prostate cancer: biologic interactions and clinical potentials. 
Cancer Metastasis Rev. 1998-1999;17(4):353-60
41 Zhao XY and Feldman D. The role of vitamin D in prostate cancer. Steroids 2001 Mar-
May;66(3-5):293-300 
42 Beer TM and Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol. 
Cancer Ther. 2004 Mar;3(3):373-81 
43 Giovannucci E, Liu Y, Rimm EB, et al. Prospective Study of Predictors of Vitamin D 
Status and Cancer Incidence and Mortality in Men. Journal of the National Cancer 
Institute 2006, 98(7):451-459.
44Giovanucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate 
cancer incidence and progression in the health professionals follow-up study. Int J 
Cancer. 2007 Oct 1;121(7):1571-8.
45 Beer TM and Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer 
Research. 2006 Jul-Aug;26(4A):2647-51.
46 Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL. Phase II trial of 
oral 1,25-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urol 
Oncol, 1995;1:195–8
47 Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate 
cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol, 1998;159:2035–9; discussion 
2039–40
48 Johnson CS, Hershberger PA, Bernardi RJ, McGuire TF, Trump DL. Vitamin D 
receptor: a potential target for intervention. Urology, 2002;60:123–30; discussion 130–21
49 Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-
dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin 
Oncol, 2003;21:123–8
50 Ahmed S, Johnson CS, Rueger RM, et al. Calcitriol (1,25-dihydroxycholecalciferol) 
potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate 
cancer model. J Urol. 2002;168:756–761
51 Beer TM, Hough KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in 
advanced prostate cancer. Semin Oncol. 2001;28(suppl 15):49–55
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 30 of 31
52 Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in 
metastatic androgen-independent prostate cancer. J Clin Oncol. 2003; 21:123–128.
53 Johnson CS, Muindi JR, Hershberger PA, Trump DL. The antitumor efficacy of 
calcitriol: preclinical studies. Anticancer Res. 2006 Jul-Aug;26(4A):2543-9. 
54 Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, 
intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-
independent prostate cancer. Cancer. 2006 May 15;106(10):2136-42
55 Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of 
vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr 
Cancer. 2005;51(1):32-6.
56 Veith R, Choo R, Deboer L, Danjoux C, Morton GC and Klotz L. Rise in prostate-
specific antigen in men with untreated low-grade prostate cancer is slower during spring-
summer. AmJ Ther. 2006 Sep-Oct;13(5):394-9
57 M.F. Holick, Vitamin D: the underappreciated D-lightful hormone that is important for 
skeletal and cellular health, Curr. Opin. Endocrinol. Diabetes 9 (2002), pp. 87–98.
58 M.J. Barger-Lux and R.P. Heaney, Effects of above average summer sun exposure on 
serum 25-hydroxyvitamin D and calcium absorption, J. Clin. Endocrinol. Metab. 87 
(2002) (11), pp. 4952–4956.
59 Heaney RP. The Vitamin D requirement in health and disease. J Steroid Biochem Mol 
Biol. 2005 Oct; 97(1-2):13-19.
60 Vieth, R., Chan, P.C.R. & MacFarlane, G. D. (2001) Efficacy and safety of vitamin D3 
intake exceeding the lowest observed adverse effect level (LOAEL). Am. J. Clin. Nutr. 
73:288-294.
61 Heaney, R. P., Davies, K. M., Chen, T. C., Holick, M. F. & Barger-Lux, M. J. (2003) 
Human serum 25-hydroxycholecalciferol response to extended oral dosing with 
cholecalciferol. Am. J. Clin. Nutr. 77:204-210
62 R.P. Heaney, K.M. Davies, T.C. Chen, M.F. Holick and M.J. Barger-Lux, Human 
serum 25-hydroxy-cholecalciferol response to extended oral dosing with cholecalciferol, 
Am. J. Clin. Nutr. 77 (2003), pp. 204–210.
63 M.J. Barger-Lux, R.P. Heaney, S. Dowell, T.C. Chen and M.F. Holick, Vitamin D and 
its major metabolites: serum levels after graded oral dosing in healthy men, Osteoporos. 
Int. 8 (1998), pp. 222–230.
APPROVED RPCI IRB
4/26/2018


I 128308 AMD # 17
 04/19/18
Page 31 of 31
64 R.P. Heaney, M.J. Barger-Lux, M.S. Dowell, T.C. Chen and M.F. Holick, Calcium 
absorptive effects of vitamin D and its major metabolites, J. Clin. Endocrinol. Metab. 82 
(1997), pp. 4111–4116
65 Woo TC, Choo R, Jamieson M, et al. Pilot study: potential role of vitamin D 
(Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer 2005: 
51(1):32-39.
66 Gross C, Stamey T, hancock S, Feldman D. Treatment of early recurrent prostate 
cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J urol 1998; 159 (6): 2035-9.
67 Clements MR, Davies M, Hayes ME, Mawer EB, Adams PH. The role of 1,25-
dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol 
1992;37:17–27.
68 Stamp TC, Haddad JG, Twigg CA. Comparison of oral 25-hydroxycholecalciferol, 
vitamin D, and ultraviolet light as determinants of circulating 25-hydroxyvitamin D. 
Lancet 1977;1:1341–3.
69 Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety.
Am J Clin Nutr. 1999 May;69(5):842-56. Review.
70 Davie MW, Lawson DE, Emberson C, Barnes JL, Roberts GE, Barnes ND. Vitamin D 
from skin: contribution to vitamin D status compared with oral vitamin D in normal and 
anticonvulsant-treated subjects. Clin Sci 1982;63:461–72
APPROVED RPCI IRB
4/26/2018